GenSci111
/ GeneScience
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 30, 2026
GenSciP111: A novel lung-targeting CCN2 siRNA for pulmonary fibrosis
(ERS 2026)
- "Through lung-targeted delivery, GenSciP111 demonstrates potent, lung-specific CCN2 silencing and significant anti-fibrotic efficacy in preclinical models. This supports its development as a first-in-class, pulmonary-delivered siRNA therapy for pulmonary fibrosis."
Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CTGF
1 to 1
Of
1
Go to page
1